Coloplast (BMV:0QBO N) - Cotización, noticias y análisis

Resumen de acción 0QBO N

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Saber más

Análisis fundamental de 0QBO N
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	3/6
Rendimiento pasado	3/6
Salud financiera	2/6
Dividendos	3/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 10.99%

Los beneficios aumentaron un 1.2% el pasado año

Análisis de riesgos

Acciones altamente ilíquidas

Tiene un alto nivel de endeudamiento

Competidores de Coloplast A/S

Cooper Companies

NasdaqGS:COO

US$19.8b

Alcon

SWX:ALC

CHF 37.8b

HOYA

TSE:7741

JP¥7.0t

Align Technology

NasdaqGS:ALGN

US$16.7b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Coloplast
Precios históricos de las acciones
Precio actual de la acción	DKK 2,082.59
Máximo en las últimas 52 semanas	DKK 2,427.29
Mínimo de 52 semanas	DKK 2,082.59
Beta	0.22
1Cambio en 1 mes	0%
Variación en 3 meses	n/a
Cambio de 1 año	n/a
3Variación en 3 años	n/a
Variación en 5 años	26.87%
Variación desde la OPV	65.47%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0QBO N	MX Medical Equipment	Mercado MX
7D	0%	0%	0%
1Y	n/a	0%	0%

Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de 0QBO N en comparación con la industria MX Medical Equipment.

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de 0QBO N frente al mercado MX.

Volatilidad de los precios

Is 0QBO N's price volatile compared to industry and market?
0QBO N volatility
0QBO N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: 0QBO N no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 0QBO N en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1954	14,973	Kristian Villumsen	www.coloplast.com

Resumen de fundamentos de Coloplast A/S

¿Cómo se comparan los beneficios e ingresos de Coloplast con su capitalización de mercado?
Estadísticas fundamentales de 0QBO N
Capitalización bursátil	Mex$499.55b
Beneficios(TTM)	Mex$12.47b
Ingresos (TTM)	Mex$62.55b

40.0x

Ratio precio-beneficio (PE)

8.0x

Ratio precio-ventas (PS)

¿Está 0QBO N sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0QBO N
Ingresos	DKK 24.07b
Coste de los ingresos	DKK 7.68b
Beneficio bruto	DKK 16.39b
Otros gastos	DKK 11.59b
Beneficios	DKK 4.80b

Últimos beneficios comunicados

Mar 31, 2023

Próxima fecha de beneficios

Aug 17, 2023

Beneficios por acción (BPA)	22.60
Margen bruto	68.09%
Margen de beneficio neto	19.94%
Ratio deuda/patrimonio	295.4%

¿Cómo se ha desempeñado 0QBO N a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.2%

Rentabilidad actual por dividendo

88%

Ratio de pagos

Resumen de acción 0QBO N

Recompensas

Análisis de riesgos

Competidores de Coloplast A/S

NasdaqGS:COO

US$19.8b

SWX:ALC

CHF 37.8b

TSE:7741

JP¥7.0t

NasdaqGS:ALGN

US$16.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Coloplast A/S

40.0x

8.0x

Beneficios e Ingresos

Dividendos

2.2%

88%